K145 HCl salt
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H558222

CAS#: 1449240-68-9 (HCl)

Description: K145 is a selective sphingosine kinase-2 (SphK2) inhibitor and anticancer agent. K145 inhibited the activity of SphK2 in a dose-dependent manner with an IC50 of 4.30±0.06 µM. K145 also exhibited inhibitory effects on the growth of U937 cells as well as apoptotic effects in U937 cells. K145 exhibits comparable in vivo anti-tumor activity to tamibarotene, while concomitantly exhibiting less toxicity in this U937 xenograft cancer model.


Chemical Structure

img
K145 HCl salt
CAS# 1449240-68-9 (HCl)

Theoretical Analysis

Hodoodo Cat#: H558222
Name: K145 HCl salt
CAS#: 1449240-68-9 (HCl)
Chemical Formula: C18H24N2O3S
Exact Mass: 348.15
Molecular Weight: 348.460
Elemental Analysis: C, 62.04; H, 6.94; N, 8.04; O, 13.77; S, 9.20

Price and Availability

Size Price Availability Quantity
5mg USD 90 Ready to ship
10mg USD 150 Ready to ship
25mg USD 250 Ready to ship
50mg USD 450 Ready to ship
100mg USD 750 Ready to ship
200mg USD 1350 Ready to ship
500mg USD 2850 Ready to ship
Bulk inquiry

Related CAS #: 1449240-68-9 (HCl)   1309444-75-4 (free base)    

Synonym: K145; K-145; K 145; K145 HCl; K145 hydrochloride.

IUPAC/Chemical Name: (Z)-3-(2-aminoethyl)-5-(3-(4-butoxyphenyl)propylidene)thiazolidine-2,4-dione hydrochloride

InChi Key: HADFDMGQKBGVAV-NKBLJONXSA-N

InChi Code: InChI=1S/C18H24N2O3S.ClH/c1-2-3-13-23-15-9-7-14(8-10-15)5-4-6-16-17(21)20(12-11-19)18(22)24-16;/h6-10H,2-5,11-13,19H2,1H3;1H/b16-6-;

SMILES Code: O=C(N(CCN)C/1=O)SC1=C/CCC2=CC=C(OCCCC)C=C2.[H]Cl

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, and in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO or water.

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:  Related CAS#: CAS#1449240-68-9 (K145 HCl salt); CAS#1309444-75-4 (K145 free base)       

Biological target: K145 hydrochloride is a SphK2 inhibitor with an IC50 of 4.3 µM.
In vitro activity: The anti-proliferative and apoptotic effects of K145 in U937 cells were evaluated. As shown in Figure 6A, K 145 significantly inhibited the growth of U937 cells cultured in the presence of 10% serum in a concentration-dependent manner. K145 also significantly induced apoptosis in U937 cells under these experimental conditions (Figure 6B). Notably, K145 induced mainly late apoptosis with a very small percentage of necrotic cells after 24 h treatment in the presence of 10% serum. Reference: PLoS One. 2013;8(2):e56471. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577900/
In vivo activity: The anticancer activity of K145 to inhibit the tumor growth of U937 cells was examined in nude mice (BALB/c-nu) by oral administration. As shown in Figure 10A, tumor weights of K145-treated mice were significantly less than that in vehicle-treated mice and K145 exhibited antitumor activity (TGI for K145 was 51.25%). Visual examination of the tumor samples also confirmed the significant inhibition of U937 tumor growth by K145 (Figure 10B-C). Collectively, the results of in vivo studies with K145 by oral administration demonstrated that K145 is orally available to inhibit the growth of U937 tumors at 50 mg/kg dose. Reference: PLoS One. 2013;8(2):e56471. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577900/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
Water 126.7 363.60
DMSO 30.0 86.09
DMSO:PBS (pH 7.2) (1:1) 0.5 1.43
DMF 10.0 28.70

Preparing Stock Solutions

The following data is based on the product molecular weight 348.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Shi Y, Qiao J, Mu B, Zuo B, Yuan J. 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) ameliorated dexamethasone induced hepatic gluconeogenesis through activation of Akt/FoxO1 pathway. Biochem Biophys Res Commun. 2017 Nov 4;493(1):286-290. doi: 10.1016/j.bbrc.2017.09.029. Epub 2017 Sep 11. PMID: 28911865. 2. Liu K, Guo TL, Hait NC, Allegood J, Parikh HI, Xu W, Kellogg GE, Grant S, Spiegel S, Zhang S. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. PLoS One. 2013;8(2):e56471. doi: 10.1371/journal.pone.0056471. Epub 2013 Feb 20. PMID: 23437140; PMCID: PMC3577900.
In vitro protocol: 1. Shi Y, Qiao J, Mu B, Zuo B, Yuan J. 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) ameliorated dexamethasone induced hepatic gluconeogenesis through activation of Akt/FoxO1 pathway. Biochem Biophys Res Commun. 2017 Nov 4;493(1):286-290. doi: 10.1016/j.bbrc.2017.09.029. Epub 2017 Sep 11. PMID: 28911865. 2. Liu K, Guo TL, Hait NC, Allegood J, Parikh HI, Xu W, Kellogg GE, Grant S, Spiegel S, Zhang S. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. PLoS One. 2013;8(2):e56471. doi: 10.1371/journal.pone.0056471. Epub 2013 Feb 20. PMID: 23437140; PMCID: PMC3577900.
In vivo protocol: 1. Shi Y, Qiao J, Mu B, Zuo B, Yuan J. 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) ameliorated dexamethasone induced hepatic gluconeogenesis through activation of Akt/FoxO1 pathway. Biochem Biophys Res Commun. 2017 Nov 4;493(1):286-290. doi: 10.1016/j.bbrc.2017.09.029. Epub 2017 Sep 11. PMID: 28911865. 2. Liu K, Guo TL, Hait NC, Allegood J, Parikh HI, Xu W, Kellogg GE, Grant S, Spiegel S, Zhang S. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. PLoS One. 2013;8(2):e56471. doi: 10.1371/journal.pone.0056471. Epub 2013 Feb 20. PMID: 23437140; PMCID: PMC3577900.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

 1: Liu K, Guo TL, Hait NC, Allegood J, Parikh HI, Xu W, Kellogg GE, Grant S, Spiegel S, Zhang S. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. PLoS One. 2013;8(2):e56471. doi: 10.1371/journal.pone.0056471. Epub 2013 Feb 20. PubMed PMID: 23437140; PubMed Central PMCID: PMC3577900.

1. Bennett MK, Li M, Tea MN, Pitman MR, Toubia J, Wang PP, Anderson D, Creek DJ, Orlowski RZ, Gliddon BL, Powell JA, Wallington-Beddoe CT, Pitson SM. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition. Neoplasia. 2022 Jan;24(1):1-11. doi: 10.1016/j.neo.2021.11.009. Epub 2021 Nov 23. PMID: 34826777; PMCID: PMC8626806.

2. Al-Shujairi WH, Clarke JN, Davies LT, Pitman MR, Calvert JK, Aloia AL, Pitson SM, Carr JM. In vitro and in vivo roles of sphingosine kinase 2 during dengue virus infection. J Gen Virol. 2019 Apr;100(4):629-641. doi: 10.1099/jgv.0.001245. Epub 2019 Mar 14. PMID: 30869582.

3. Wallington-Beddoe CT, Bennett MK, Vandyke K, Davies L, Zebol JR, Moretti PAB, Pitman MR, Hewett DR, Zannettino ACW, Pitson SM. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress. Oncotarget. 2017 Jul 4;8(27):43602-43616. doi: 10.18632/oncotarget.17115. PMID: 28467788; PMCID: PMC5546428.